TargetMol

CRBN Molecular Glues Library

Product Code:
 
TAR-L9800
Product Group:
 
Compound Libraries
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
Dry ice
Storage:
 
-20°C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-L9800-10uL10 uL x 10 mM (in DMSO)£52,475.00
Additional shipping charges apply. Please contact us for a quote.
Quantity:
TAR-L9800-25uL25 uL x 10 mM (in DMSO)£87,802.00
Additional shipping charges apply. Please contact us for a quote.
Quantity:
TAR-L9800-50uL50 uL x 10 mM (in DMSO)£135,080.00
Additional shipping charges apply. Please contact us for a quote.
Quantity:
TAR-L9800-100uL100 uL x 10 mM (in DMSO)£182,815.00
Additional shipping charges apply. Please contact us for a quote.
Quantity:
TAR-L9800-200uL200 uL x 10 mM (in DMSO)£291,150.00
Additional shipping charges apply. Please contact us for a quote.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Austria.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Show All

Further Information

Number of Compounds:
Inquiry
Short Description:

- A collection of 6,444 newly designed and synthesized molecular glue structures, suitable for research on CRBN-targeting molecular glue drugs;
- Selected CRBN warheads with reported experimental validation, further optimized using an AI-driven molecular generation system to design highly reliable candidate CRBN-targeting molecular glues;
- In addition to lenalidomide-like scaffolds, the library includes diverse non-lenalidomide spirocyclic frameworks, offering new opportunities for novel scaffold discovery;
- Undergone structural diversification and drug-likeness filtering, ensuring good structural representativeness and favorable druggability properties;
- Validated through small-scale random screening, demonstrating a significantly higher hit rate compared to CRBN warhead compounds from other commercial sources.